HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Genmab (NASDAQ:GMAB) and maintained a $50 price target.

February 20, 2024 | 12:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Genmab's stock rating was reiterated as Buy by HC Wainwright & Co. with a maintained price target of $50.
The reiteration of a Buy rating and maintenance of a $50 price target by a reputable analyst firm like HC Wainwright & Co. typically signals continued confidence in the company's future performance. This can positively influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100